Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA
Kiadis Pharma announces that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc™ Orphan Drug Designations (ODD) for the treatment of two types of non-Hodgkin lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc™ is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.
“This is an important strategic milestone in the development of Reviroc™ and we are very pleased with the orphan drug designations received from the FDA”, says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.